November 2017

Global T-Cell Lymphoma Market – Growth, Trends and Forecasts (2017 – 2022)

Purchase Report
Single user license
Team license
Corporate license

T-Cell Lymphoma Market 

The market is expected to grow at a CAGR of XX% during the forecast period 2017-2022. The market was valued at USD XX million in 2016 and is forecasted to reach USD XX million by 2022.

Non-Hodgkin's lymphoma caused by malignant T-Cell lymphocytes represent a smaller subset (about 15% in the US) of the known types of non-Hodgkin's lymphoma - approximately 6,885 new cases are diagnosed, annually. Based on the (SEER) cancer registries, incidence rates for lymphoid neoplasms and Hodgkin lymphoma were found to be 2.09 and 2.71 per 100,000 people, respectively. Within T/NK-cell lymphoid neoplasms, incidence rates were highest for peripheral T-cell lymphoma (PTCL) (0.78), followed by mycosis fungoides/Sezary syndrome (0.54) and T/NK-cell lymphoid neoplasms, not otherwise specified (NOS) (0.49). The incidence of ATL was rare in the US (0.04). The most common PTCL subtype was PTCL-NOS (0.41), followed by anaplastic large cell lymphoma (ALCL) (0.28), cutaneous T-cell lymphoma (0.25), and angioimmunoblastic lymphoma (0.10). The remaining PTCL sub-types (subcutaneous panniculitis-like T-cell lymphoma, hepatosplenic T-cell lymphoma, enteropathy-type T-cell lymphoma) were rare and had incidence rates of 0.01 per 100,000 persons.

Global T-Cell Lymphoma - Market Dynamics

The report details several factors driving and restraining the market, some of which are discussed below.


  • Rising healthcare expenditure
  • Numerous chemotherapy agents driving the market
  • Reimbursement policies covering cancer therapies


  • Poor incidence rate
  • Low awareness about lymphoma and treatment options
  • Adverse side effects of the therapies

Market Segmentation

The global T-cell lymphoma market has been segmented by type of disease into extranodal T-cell lymphoma, cutaneous T-cell lymphoma, anaplastic large cell lymphoma, and angioimmunoblastic T-cell lymphoma. The market, by treatment type, is divided into radiotherapy, chemotherapy, stem cell transplantation, and surgery. The chemotherapy treatment includes major drugs such as Bexarotene (Targretin), Denileukin Diftitox (Ontak), Romidepsin (Istodax), And Vorinostat (Zolinza), among many others. The market has been geographically segmented into North America, Europe, Asia-Pacific, and Rest of the World.

Some of the key players in the market are:

  • Actelion Pharmaceuticals
  • Allos Therapeutics
  • Astellas Pharma
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eisai
  • Genmab
  • Galderma
  • Inovio Pharmaceuticals
  • Johnson & Johnson Pharmaceutical Research & Development
  • Novartis
  • Onyx Pharmaceuticals
  • Roche
  • Seattle Genetics
  • Others

What the Report Offers

  • Market definition, along with identification of key drivers and restraints for the market.
  • Market analysis with region-specific assessments and competition analysis on a global and regional scale.
  • Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
  • Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
  • Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.
  • A comprehensive list of key market players, along with the analysis of their current strategic interests and key financial information.
  • An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain critical insight into the factors driving and restraining the market, in addition to opportunities, offered.
No related reports available.
Purchase Report
Single user license
Team license
Corporate license
Our Clients Include View All

Looking to Customize Report?